{"slideshow_credits": null, "snippet": "Federal officials have approved a cheaper version of Johnson &amp; Johnson\u2019s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.", "abstract": "Food and Drug Administration approves Celltrion and Pfizer's quasi generic drug Inflectra, less expensive version of Remicade, Johnson & Johnson's costly biotech drug for treatment of inflammatory diseases.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "original": "By THE ASSOCIATED PRESS", "organization": "THE ASSOCIATED PRESS"}, "web_url": "http://www.nytimes.com/2016/04/06/business/fda-clears-cheaper-version-of-johnson-johnson-biologic.html", "lead_paragraph": "Federal officials have approved a cheaper version of Johnson &amp; Johnson\u2019s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.", "headline": {"print_headline": "F.D.A. Clears Cheaper Version of Johnson &amp; Johnson Biologic", "main": "F.D.A. Clears Cheaper Version of Johnson &amp; Johnson Biologic", "content_kicker": "Business Briefing", "kicker": "Business Briefing"}, "_id": "57045b2c38f0d848959bee30", "word_count": "165", "multimedia": [], "pub_date": "2016-04-06T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Pfizer Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Celltrion Inc", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "Johnson & Johnson", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Generic Brands and Products", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Remicade (Drug)", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "News"}